Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?

Targeting Neuroinflammation to Alleviate Chronic Olfactory Dysfunction in Long COVID: A Role for Investigating Disease-Modifying Therapy (DMT)?

Chronic olfactory dysfunction after SARS-CoV-2 infection occurs in approximately 10% of patients with COVID-19-induced anosmia, and it is a growing public health concern. A regimen of olfactory training and anti-neuroinflammatory therapy with co-ultramicronized palmitoylethanolamide with luteolin (u...

Full description

Bibliographic Details
Main Authors: Arianna Di Stadio, Evanthia Bernitsas, Ignazio La Mantia, Michael J. Brenner, Massimo Ralli, Luigi Angelo Vaira, Andrea Colizza, Carlo Cavaliere, Matteo Laudani, Teresa C. Frohman, Marco De Vincentiis, Elliot M. Frohman, Marta Altieri
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Life
Subjects:
COVID-19
anosmia
hyposmia
smell disorders
multiple sclerosis
disease-modifying therapy
Online Access:https://www.mdpi.com/2075-1729/13/1/226

Internet

https://www.mdpi.com/2075-1729/13/1/226

Similar Items